Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
What is Tremfya and how is it used?
Tremfya is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet or UV light). It is not known if Tremfya is safe and effective in children under 18 years of age.
What are the possible side effects of Tremfya?
Tremfya may cause serious side effects including:
These are not all the possible side effects of Tremfya. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Guselkumab, an interleukin-23 blocker, is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. Guselkumab is produced in a mammalian cell line using recombinant DNA technology.
TREMFYA (guselkumab) Injection is a sterile, preservative free, clear, colorless to light yellow solution that may contain small translucent particles. Each single-dose prefilled syringe for subcutaneous use contains 100 mg of guselkumab in 1 mL. TREMFYA is supplied as a single-dose solution in a 1 mL glass syringe with a 27G, half inch fixed needle assembled in a passive needle guard delivery system.
Each TREMFYA prefilled syringe delivers 1 mL of solution containing guselkumab (100 mg), L-histidine (0.6 mg), L-histidine monohydrochloride monohydrate (1.5 mg), polysorbate 80 (0.5 mg), sucrose (79 mg) and water for injection at pH 5.8.
TREMFYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
TREMFYA is indicated for the treatment of adult patients with active psoriatic arthritis.
TREMFYA is administered by subcutaneous injection. The recommended dose is 100 mg at Week 0, Week 4, and every 8 weeks thereafter.
TREMFYA is administered by subcutaneous injection. The recommended dose is 100 mg at Week 0, Week 4, and every 8 weeks thereafter.
TREMFYA may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).
Administer TREMFYA subcutaneously. Each prefilled syringe or One-Press injector is for single-dose only. Instruct patients to inject the full amount (1 mL), which provides 100 mg of TREMFYA.
Do not inject TREMFYA into areas where the skin is tender, bruised, red, hard, thick, scaly, or affected by psoriasis [see Instructions For Use].
TREMFYA is intended for use under the guidance and supervision of a physician. TREMFYA may be administered by a health care professional, or a patient may self-inject after proper training in subcutaneous injection technique.
The TREMFYA Instructions for Use contains more detailed patient instructions on the preparation and administration of TREMFYA [see Instructions for Use].
Before injection, remove TREMFYA prefilled syringe or One-Press injector from the refrigerator and allow TREMFYA to reach room temperature (30 minutes) without removing the needle cap.
Inspect TREMFYA visually for particulate matter and discoloration prior to administration. TREMFYA is a clear and colorless to light yellow solution that may contain small translucent particles. Do not use if the liquid contains large particles, is discolored or cloudy. TREMFYA does not contain preservatives; therefore, discard any unused product remaining in the prefilled syringe or One-Press injector.
Injection: 100 mg/mL in a single-dose prefilled syringe or single-dose One-Press patient-controlled injector.
TREMFYA is a clear and colorless to light yellow solution that may contain small translucent particles.
TREMFYA (guselkumab) Injection is a clear and colorless to light yellow solution that may contain small translucent particles. TREMFYA is supplied as:
Single-dose 100 mg/mL prefilled syringe (NDC: 57894-640-01)
Single-dose 100 mg/mL One-Press patient-controlled injector (NDC: 57894-640-11)
TREMFYA is sterile and preservative-free. Discard any unused portion.
Manufactured by: Janssen Biotech, Inc., Horsham, PA 19044, US License No. 1864. Revised: Jul 2020
The following adverse reactions are discussed in greater detail in other sections of labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In clinical trials, a total of 1823 subjects with moderate-to-severe plaque psoriasis received TREMFYA. Of these, 1393 subjects were exposed to TREMFYA for at least 6 months and 728 subjects were exposed for at least 1 year.
Data from two placebo- and active-controlled trials (PsO1 and PsO2) in 1441 subjects (mean age 44 years; 70% males; 82% white) were pooled to evaluate the safety of TREMFYA (100 mg administered subcutaneously at Weeks 0 and 4, followed by every 8 weeks).
In the 16-week placebo-controlled period of the pooled clinical trials (PsO1 and PsO2), adverse events occurred in 49% of subjects in the TREMFYA group compared to 47% of subjects in the placebo group and 49% of subjects in the U.S. licensed adalimumab group. Serious adverse events occurred in 1.9% of subjects in the TREMFYA group (6.3 events per 100 subject-years of follow-up) compared to 1.4% of subjects in the placebo group (4.7 events per 100 subject-years of follow-up), and in 2.6% of subjects in U.S. licensed adalimumab group (9.9 events per 100 subject-years of follow-up).
Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the TREMFYA group than in the placebo group during the 16-week placebo-controlled period.
Table 1: Adverse Reactions Occurring in ≥1% of Subjects through Week 16 in PsO1 and PsO2
| TREMFYAa 100 mg N=823 n (%) | Adalimumabb N=196 n (%) | Placebo N=422 n (%) | |
| Upper respiratory infectionsc | 118 (14.3) | 21 (10.7) | 54 (12.8) |
| Headached | 38 (4.6) | 2 (1.0) | 14 (3.3) |
| Injection site reactionse | 37 (4.5) | 15 (7.7) | 12 (2.8) |
| Arthralgia | 22 (2.7) | 4 (2.0) | 9 (2.1) |
| Diarrhea | 13 (1.6) | 3 (1.5) | 4 (0.9) |
| Gastroenteritisf | 11 (1.3) | 4 (2.0) | 4 (0.9) |
| Tinea infectionsg | 9(1.1) | 0 | 0 |
| Herpes simplex infectionsh | 9(1.1) | 0 | 2 (0.5) |
| a Subjects receiving 100 mg of TREMFYA at Week 0, Week 4, and every 8 weeks thereafter b U.S. licensed adalimumab c Upper respiratory infections include nasopharyngitis, upper respiratory tract infection (URTI), pharyngitis, and viral URTI. d Headache includes headache and tension headache. e Injection site reactions include injection site erythema, bruising, hematoma, hemorrhage, swelling, edema, pruritus, pain, discoloration, induration, inflammation, and urticaria. f Gastroenteritis includes gastroenteritis and viral gastroenteritis. g Tinea infections include tinea pedis, tinea cruris, tinea infection, and tinea manuum infections. h Herpes simplex infections include oral herpes, herpes simplex, genital herpes, genital herpes simplex, and nasal herpes simplex. | |||
Adverse reactions that occurred in < 1% but > 0.1% of subjects in the TREMFYA group and at a higher rate than in the placebo group through Week 16 in PsO1 and PsO2 were migraine, candida infections, and urticaria.
Infections occurred in 23% of subjects in the TREMFYA group compared to 21% of subjects in the placebo group.
The most common (≥ 1%) infections were upper respiratory infections, gastroenteritis, tinea infections, and herpes simplex infections; all cases were mild to moderate in severity and did not lead to discontinuation of TREMFYA.
Elevated liver enzymes were reported more frequently in the TREMFYA group (2.6%) than in the placebo group (1.9%). Of the 21 subjects who were reported to have elevated liver enzymes in the TREMFYA group, all events except one were mild to moderate in severity and none of the events led to discontinuation of TREMFYA.
Through Week 48, no new adverse reactions were identified with TREMFYA use and the frequency of the adverse reactions was similar to the safety profile observed during the first 16 weeks of treatment.
TREMFYA was studied in two placebo-controlled trials in subjects with psoriatic arthritis (748 subjects on TREMFYA and 372 subjects on placebo). Of the 748 subjects who received TREMFYA, 375 subjects received TREMFYA 100 mg at Week 0, Week 4, and every 8 weeks thereafter and 373 subjects received TREMFYA 100 mg every 4 weeks. The overall safety profile observed in subjects with psoriatic arthritis treated with TREMFYA is generally consistent with the safety profile in subjects with plaque psoriasis with the addition of bronchitis and neutrophil count decreased. In the 24-week placebo-controlled period, combined across the two studies, bronchitis occurred in 1.6% of subjects in the TREMFYA q8w group and 2.9% of subjects in the TREMFYA q4w group compared to 1.1% of subjects in the placebo group. Neutrophil count decreased occurred in 0.3% of subjects in the TREMFYA q8w and 1.6% of subjects in the TREMFYA q4w group compared to 0% of subjects in the placebo group. The majority of events of neutrophil count decreased were mild, transient, not associated with infection and did not lead to discontinuation.
As with all therapeutic proteins, there is the potential for immunogenicity with TREMFYA. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to guselkumab across indications or with the incidences of antibodies to other products may be misleading.
Up to Week 52, approximately 6% of subjects treated with TREMFYA developed antidrug antibodies. Of the subjects who developed antidrug antibodies, approximately 7% had antibodies that were classified as neutralizing antibodies. Among the 46 subjects who developed antibodies to guselkumab and had evaluable data, 21 subjects exhibited lower trough levels of guselkumab, including one subject who experienced loss of efficacy after developing high antibody titers. Up to Week 156, approximately 9% of subjects treated with TREMFYA developed antidrug antibodies and of these subjects approximately 6% were classified as neutralizing antibodies. However, antibodies to guselkumab were generally not associated with changes in clinical response or development of injection-site reactions.
Up to Week 24, 2% (n=15) of subjects treated with TREMFYA developed antidrug antibodies. Of these subjects, 1 had antibodies that were classified as neutralizing antibodies. Overall, the small number of subjects who were positive for antibodies to guselkumab limits definitive conclusion of the effect of immunogenicity on the pharmacokinetics, efficacy and safety of guselkumab.
The following adverse reactions have been reported during post-approval of TREMFYA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to TREMFYA exposure.
Immune system disorders: Hypersensitivity, including anaphylaxis [see WARNINGS AND PRECAUTIONS]
Skin and subcutaneous tissue disorders: Rash [see WARNINGS AND PRECAUTIONS]
The formation of CYP450 enzymes can be altered by increased levels of certain cytokines (e.g., IL-1, IL-6, IL-10, TNFα, interferon) during chronic inflammation.
Results from an exploratory drug-drug interaction study in subjects with moderate-to-severe plaque psoriasis suggested a low potential for clinically relevant drug interactions for drugs metabolized by CYP3A4, CYP2C9, CYP2C19 and CYP1A2 but the interaction potential cannot be ruled out for drugs metabolized by CYP2D6. However, the results were highly variable because of the limited number of subjects in the study.
Upon initiation of TREMFYA in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or drug concentration and consider dosage adjustment as needed [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Serious hypersensitivity reactions, includinga anaphylaxis, have been reported with postmarket use of TREMFYA. Some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA and initiate appropriate therapy.
TREMFYA may increase the risk of infection. In clinical trials in subjects with plaque psoriasis, infections occurred in 23% of subjects in the TREMFYA group versus 21% of subjects in the placebo group through 16 weeks of treatment. Upper respiratory tract infections, gastroenteritis, tinea infections, and herpes simplex infections occurred more frequently in the TREMFYA group than in the placebo group [see ADVERSE REACTIONS]. The rate of serious infections for the TREMFYA group and the placebo group was ≤ 0.2%. A similar risk of infection was seen in placebo-controlled trials in subjects with psoriatic arthritis. Treatment with TREMFYA should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing TREMFYA. Instruct patients to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TREMFYA until the infection resolves.
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TREMFYA. Initiate treatment of latent TB prior to administering TREMFYA. In clinical trials, 105 subjects with plaque psoriasis and 71 subjects with psoriatic arthritis with latent TB who were concurrently treated with TREMFYA and appropriate TB prophylaxis did not develop active TB. Monitor patients for signs and symptoms of active TB during and after TREMFYA treatment.
Consider anti-TB therapy prior to initiating TREMFYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Do not administer TREMFYA to patients with active TB infection.
Prior to initiating therapy with TREMFYA, consider completion of all age appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA. No data are available on the response to live or inactive vaccines.
Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) before starting TREMFYA therapy, and each time the prescription is renewed, as there may be new information they need to know.
Advise patients to discontinue TREMFYA and seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions [see WARNINGS AND PRECAUTIONS].
Instruct patients of the importance of communicating any history of infections to the healthcare provider and contacting their healthcare provider if they develop any symptoms of an infection [see WARNINGS AND PRECAUTIONS].
Instruct patients or caregivers to perform the first self-injection under the supervision and guidance of a qualified healthcare professional for proper training in subcutaneous injection technique. Instruct patients who are self-administering to inject the full dose of TREMFYA [see Medication Guide and Instructions for Use].
Instruct patients or caregivers in the technique of proper needle and syringe disposal. Needles and syringes should be disposed of in a puncture-resistant container. Advise patients and caregivers not to reuse needles or syringes.
Remind patients if they forget to take their dose of TREMFYA to inject their dose as soon as they remember. They should then take their next dose at the appropriate scheduled time.
Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TREMFYA.
No effects on fertility parameters were observed after male guinea pigs were subcutaneously administered guselkumab at a dose of 25 mg/kg twice weekly (15 times the MRHD based on a mg/kg comparison).
No effects on fertility parameters were observed after female guinea pigs were subcutaneously administered guselkumab at doses up to 100 mg/kg twice weekly (60 times the MRHD based on a mg/kg comparison).
There is a pregnancy registry that monitors pregnancy outcomes in women exposed to TREMFYA during pregnancy. Patients should be encouraged to enroll by calling 1-877-311- 8972.
There are no available data on TREMFYA use in pregnant women to inform a drug associated risk of adverse developmental outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, TREMFYA may be transmitted from the mother to the developing fetus. In a combined embryofetal development and pre- and post-natal development study, no adverse developmental effects were observed in infants born to pregnant monkeys after subcutaneous administration of guselkumab during organogenesis through parturition at doses up to 30 times the maximum recommended human dose (MRHD). Neonatal deaths were observed at 6- to 30-times the MRHD (see Data). The clinical significance of these nonclinical findings is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Animal Data
In a combined embryofetal development and pre- and post-natal development study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of guselkumab up to 50 mg/kg (30 times the MRHD based on a mg/kg comparison) from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of one control monkey, three monkeys administered guselkumab at 10 mg/kg/week (6 times the MRHD based on a mg/kg comparison) and three monkeys administered guselkumab at 50 mg/kg/week (30 times the MRHD based on a mg/kg comparison). The clinical significance of these findings is unknown. No guselkumab-related effects on functional or immunological development were observed in the infants from birth through 6 months of age.
There are no data on the presence of guselkumab in human milk, the effects on the breastfed infant, or the effects on milk production. Guselkumab was not detected in the milk of lactating cynomolgus monkeys. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TREMFYA and any potential adverse effects on the breastfed infant from TREMFYA or from the underlying maternal condition.
The safety and efficacy of TREMFYA in pediatric patients (less than 18 years of age) have not been established.
Of the 3406 subjects with plaque psoriasis or psoriatic arthritis exposed to TREMFYA, a total of 185 subjects were 65 years or older, and 13 subjects were 75 years or older. No overall differences in safety or effectiveness were observed between older and younger subjects who received TREMFYA. However, the number of subjects aged 65 years and older was not sufficient to determine whether they respond differently from younger subjects [see CLINICAL PHARMACOLOGY].
In the event of overdosage, monitor the patient for any signs or symptoms of adverse reactions and administer appropriate symptomatic treatment immediately.
TREMFYA is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients [see WARNINGS AND PRECAUTIONS].
Guselkumab is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of interleukin 23 (IL-23) and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Guselkumab inhibits the release of proinflammatory cytokines and chemokines.
In evaluated subjects with plaque psoriasis, guselkumab reduced serum levels of IL-17A, IL-17F and IL-22 relative to pre-treatment levels based on exploratory analyses of the pharmacodynamic markers.
In evaluated subjects with psoriatic arthritis, serum levels of acute phase proteins C-reactive protein, serum amyloid A and IL-6, and Th17 effector cytokines IL-17A, IL-17F and IL-22 were elevated at baseline. Serum levels of these proteins measured at Week 4 and Week 24 were decreased compared to baseline following guselkumab treatment at Week 0, Week 4 and every 8 weeks thereafter.
The relationship between these pharmacodynamic markers and the mechanism(s) by which guselkumab exerts its clinical effects is unknown.
Guselkumab exhibited linear pharmacokinetics in healthy subjects and subjects with plaque psoriasis following subcutaneous injections. In subjects with plaque psoriasis, following subcutaneous administration of 100 mg of TREMFYA at Weeks 0 and 4, and every 8 weeks thereafter, mean steady-state trough serum guselkumab concentration was approximately 1.2 mcg/mL.
The pharmacokinetics of guselkumab in subjects with psoriatic arthritis was similar to that in subjects with plaque psoriasis. Following subcutaneous administration of 100 mg of TREMFYA at Weeks 0, 4, and every 8 weeks thereafter, mean steady-state trough serum guselkumab concentration was approximately 1.2 mcg/mL.
Following a single 100 mg subcutaneous injection in healthy subjects, guselkumab reached a mean (± SD) maximum serum concentration of 8.09 ± 3.68 mcg/mL by approximately 5.5 days post dose. The absolute bioavailability of guselkumab following a single 100 mg subcutaneous injection was estimated to be approximately 49% in healthy subjects.
In subjects with plaque psoriasis, apparent volume of distribution was 13.5 L.
Apparent clearance in subjects with plaque psoriasis was 0.516 L/day. Mean half-life of guselkumab was approximately 15 to 18 days in subjects with plaque psoriasis across trials.
The exact pathway through which guselkumab is metabolized has not been characterized. As a human IgG monoclonal antibody, guselkumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.
No apparent differences in clearance were observed in subjects ≥ 65 years of age compared to subjects < 65 years of age, suggesting no dose adjustment is needed for elderly subjects. Clearance and volume of distribution of guselkumab increases as body weight increases, however, observed clinical trial data indicate that dose adjustment for body weight is not warranted. No specific trials have been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of guselkumab.
Population pharmacokinetic analyses indicated that concomitant use of NSAIDs, oral corticosteroids and conventional DMARDs such as methotrexate, did not affect the clearance of guselkumab.
The effects of guselkumab on the pharmacokinetics of midazolam (metabolized by CYP3A4), warfarin (metabolized by CYP2C9), omeprazole (metabolized by CYP2C19), dextromethorphan (metabolized by CYP2D6), and caffeine (metabolized by CYP1A2) were evaluated in an exploratory study with 6 to 12 evaluable subjects with moderate-to-severe plaque psoriasis. Changes in AUCinf of midazolam, S-warfarin, omeprazole, and caffeine after a single dose of guselkumab were not clinically relevant. For dextromethorphan, changes in AUCinf after guselkumab were not clinically relevant in 9 out of 10 subjects; however, a 2.9-fold change in AUCinf was observed in one individual [see DRUG INTERACTIONS].
Four multicenter, randomized, double-blind trials (PsO1 [NCT02207231], PsO2 [NCT02207244], PsO3 [NCT02203032], and PsO4 [NCT02905331]) enrolled subjects 18 years of age and older with moderate-to-severe plaque psoriasis who were eligible for systemic therapy or phototherapy. Subjects had an Investigator’s Global Assessment (IGA) score of ≥3 (“moderate”) on a 5-point scale of overall disease severity, a Psoriasis Area and Severity Index (PASI) score ≥12, and a minimum affected body surface area (BSA) of 10%. Subjects with guttate, erythrodermic, or pustular psoriasis were excluded.
In PsO1 and PsO2, 1443 subjects were randomized to either TREMFYA (100 mg at Weeks 0 and 4 and every 8 weeks thereafter) administered with a prefilled syringe, placebo or U.S. licensed adalimumab (80 mg at Week 0 and 40 mg at Week 1, followed by 40 mg every other week thereafter).
Both trials assessed the responses at Week 16 compared to placebo for the two co-primary endpoints:
Comparisons between TREMFYA and U.S. licensed adalimumab were secondary endpoints at the following time points:
Other evaluated outcomes included improvement in psoriasis symptoms assessed on the Psoriasis Symptoms and Signs Diary (PSSD) and improvements in psoriasis of the scalp at Week 16.
In both trials, subjects were predominantly men and white, with a mean age of 44 years and a mean weight of 90 kg. At baseline, subjects had a median affected BSA of approximately 21%, a median PASI score of 19, and 18% had a history of psoriatic arthritis. Approximately 24% of subjects had an IGA score of severe. In both trials, 23% had received prior biologic systemic therapy.
Table 2 presents the efficacy results at Week 16 in PsO1 and PsO2.
Table 2: Efficacy Results at Week 16 in Adults with Plaque Psoriasis (NRIa)
| Endpoint | PsO1 | PsO2 | ||
| TREMFYA (N=329) n (%) | Placebo (N=174) n (%) | TREMFYA (N=496) n (%) | Placebo (N=248) n (%) | |
| IGA response of 0/1b,c | 280 (85) | 12 (7) | 417 (84) | 21(8) |
| PASI 90 responseb | 241 (73) | 5 (3) | 347 (70) | 6 (2) |
| a NRI = Non-Responder Imputation b Co-Primary Endpoints c IGA response of 0 (cleared) or 1 (minimal) | ||||
Table 3 presents the results of an analysis of all the North America sites (i.e., U.S. and Canada), demonstrating superiority of TREMFYA to U.S. licensed adalimumab.
Table 3: Efficacy Results in Adults with Plaque Psoriasis (NRIa)
| Endpoint | PsO1 | PsO2 | ||
| TREMFYA (N=115)b n (%) | Adalimumabc (N=115)b n (%) | TREMFYA (N=160)b n (%) | Adalimumabc (N=81)b n (%) | |
| IGA response of 0/1 (cleared or minimal) | ||||
| Week 16 | 97 (84) | 70 (61) | 119 (74) | 50 (62) |
| Week 24 | 97 (84) | 62 (54) | 119 (74) | 46 (57) |
| Week 48 | 91 (79) | 62 (54) | NA | NA |
| IGA response of 0 (cleared) | ||||
| Week 24 | 61 (53) | 27 (23) | 76 (48) | 23 (28) |
| Week 48 | 54 (47) | 28 (24) | NA | NA |
| PASI 75 response | ||||
| Week 16 | 105 (91) | 80 (70) | 132 (83) | 51 (63) |
| PASI 90 response | ||||
| Week 16 | 84 (73) | 47 (41) | 102 (64) | 34 (42) |
| Week 24 | 92 (80) | 51 (44) | 113 (71) | 41 (51) |
| Week 48 | 84 (73) | 53 (46) | NA | NA |
| a NRI = Non-Responder Imputation b Subjects from sites in the United States and Canada c U.S. licensed adalimumab | ||||
An improvement was seen in psoriasis involving the scalp in subjects randomized to TREMFYA compared to placebo at Week 16.
Examination of age, gender, race, body weight, and previous treatment with systemic or biologic agents did not identify differences in response to TREMFYA among these subgroups.
To evaluate maintenance and durability of response (PsO2), subjects randomized to TREMFYA at Week 0 and who were PASI 90 responders at Week 28 were re-randomized to either continue treatment with TREMFYA every 8 weeks or be withdrawn from therapy (i.e. receive placebo).
At Week 48, 89% of subjects who continued on TREMFYA maintained PASI 90 compared to 37% of subjects who were re-randomized to placebo and withdrawn from TREMFYA. For responders at Week 28 who were re-randomized to placebo and withdrawn from TREMFYA, the median time to loss of PASI 90 was approximately 15 weeks.
Greater improvements in symptoms of psoriasis (itch, pain, stinging, burning and skin tightness) at Week 16 in TREMFYA compared to placebo were observed in both trials based on the Psoriasis Symptoms and Signs Diary (PSSD). Greater proportions of subjects on TREMFYA compared to U.S. licensed adalimumab achieved a PSSD symptom score of 0 (symptom-free) at Week 24 in both trials.
Trial PsO3
PsO3 [NCT02203032] evaluated the efficacy of 24 weeks of treatment with TREMFYA in subjects (N=268) who had not achieved an adequate response, defined as IGA ≥2 at Week 16 after initial treatment with U.S. licensed ustekinumab (dosed 45 mg or 90 mg according to the subject’s baseline weight at Week 0 and Week 4). These subjects were randomized to either continue with U.S. licensed ustekinumab treatment every 12 weeks or switch to TREMFYA 100 mg at Weeks 16, 20, and every 8 weeks thereafter. Baseline characteristics for randomized subjects were similar to those observed in PsO1 and PsO2.
In subjects with an inadequate response (IGA ≥2 at Week 16 to U.S. licensed ustekinumab), greater proportions of subjects on TREMFYA compared to U.S. licensed ustekinumab achieved an IGA score of 0 or 1 with a ≥2 grade improvement at Week 28 (31% vs. 14%, respectively; 12 weeks after randomization).
Trial PsO4
PsO4 [NCT02905331] evaluated the efficacy, safety, and pharmacokinetics of TREMFYA administered with the One-Press injector. In this study, 78 subjects were randomized to receive either TREMFYA (100 mg at Weeks 0 and 4 and every 8 weeks thereafter) [N=62], or placebo [N=16]. Baseline characteristics for subjects were comparable to those observed in PsO1 and PsO2. The co-primary endpoints were the same as those for PsO1 and PsO2. Secondary endpoints included the proportion of subjects who achieved an IGA score of 0 at Week 16 and the proportion of subjects who achieved a PASI 100 response at Week 16.
A greater proportion of subjects in the guselkumab group achieved an IGA score of 0 or 1 or a PASI 90 response at Week 16 (81% and 76%, respectively) than in the placebo group (0% for both endpoints). The proportion of subjects who achieved an IGA score of 0 at Week 16 was higher in the guselkumab group compared to the placebo group (56% vs. 0%). The proportion of subjects who achieved a PASI 100 response at Week 16 was higher in the guselkumab group compared to the placebo group (50% vs. 0%).
The safety and efficacy of TREMFYA were assessed in 1120 subjects in 2 randomized, double-blind, placebo-controlled trials (PsA1 [NCT03162796] and PsA2 [NCT03158285]) in adult subjects with active psoriatic arthritis (PsA) (≥3 swollen joints, ≥3 tender joints, and a C-reactive protein (CRP) level of ≥0.3 mg/dL in PsA1 and ≥5 swollen joints, ≥5 tender joints, and a CRP level of ≥0.6 mg/dL in PsA2) who had inadequate response to standard therapies (e.g. conventional DMARDs [cDMARDs]), apremilast, or nonsteroidal anti-inflammatory drugs [NSAIDs]). Patients in these trials had a diagnosis of PsA for at least 6 months based on the Classification criteria for Psoriatic Arthritis (CASPAR) and a median duration of PsA of 4 years at baseline.
In PsA1 approximately 31% of subjects had been previously treated with up to 2 anti-tumor necrosis factor alpha (anti-TNFα) agents whereas in PsA2 all subjects were biologic naïve. Approximately 58% of subjects from both trials had concomitant methotrexate (MTX) use. Patients with different subtypes of PsA were enrolled in both trials, including polyarticular arthritis with the absence of rheumatoid nodules (40%), spondylitis with peripheral arthritis (30%), asymmetric peripheral arthritis (23%), distal interphalangeal involvement (7%) and arthritis mutilans (1%). At baseline, over 65% and 42% of the subjects had enthesitis and dactylitis, respectively and 79% had ≥3% body surface area (BSA) psoriasis skin involvement.
PsA1 evaluated 381 subjects who were treated with placebo SC, TREMFYA 100 mg SC at Weeks 0, 4 and every 8 weeks (q8w) thereafter, or TREMFYA 100 mg SC every 4 weeks (q4w). PsA2 evaluated 739 subjects who were treated with placebo SC, TREMFYA 100 mg SC at Weeks 0, 4 and q8w thereafter, or TREMFYA 100 mg SC q4w. The primary endpoint in both trials was the percentage of subjects achieving an ACR20 response at Week 24.
In both trials, subjects treated with TREMFYA 100 mg q8w demonstrated a greater clinical response including ACR20, compared to placebo at Week 24 (Tables 4 and 5). Similar responses were seen regardless of prior anti-TNFα exposure in PsA1, and in both trials similar responses were seen regardless of concomitant cDMARD use, previous treatment with cDMARDs, gender and body weight.
Table 4: Percent of Subjects with ACR Responses in PsA1
| Placebo (N=126) | TREMFYA 100 mg q8w (N=127) | ||
| Response Rate | Response Rate | Difference from Placebo (95% CI) | |
| ACR 20 responsea | |||
| Week 16 | 25% | 52% | 27 (15, 38) |
| Week 24 | 22% | 52% | 30(19, 41) |
| ACR 50 responsea | |||
| Week 16 | 13% | 23% | 10 (1, 19) |
| Week 24 | 9% | 30% | 21 (12, 31) |
| ACR 70 responsea | |||
| Week 16 | 6% | 8% | 2 (-4, 8) |
| Week 24 | 6% | 12% | 6 (-0.3, 13) |
| a Subjects with missing data at a visit were imputed as non-responders at that visit. Subjects who met escape criteria (less than 5% improvement in both tender and swollen joint counts) at Week 16 were allowed to initiate or increase the dose of the permitted concomitant medication and remained on the randomized group. Subjects who initiated or increased the dose of non-biologic DMARD or oral corticosteroids over baseline, discontinued study/study medication or initiated protocol prohibited medications/therapies for PsA prior to a visit were considered non-responders at that visit. | |||
Table 5: Percent of Subjects with ACR Responses in PsA2
| Placebo (N=246) | TREMFYA 100 mg q8w (N=248) | ||
| Response Rate | Response Rate | Difference from Placebo (95% CI) | |
| ACR 20 responsea | |||
| Week 16 | 34% | 55% | 22 (13, 30) |
| Week 24 | 33% | 64% | 31 (23, 40) |
| ACR 50 responsea | |||
| Week 16 | 9% | 29% | 19(13, 26) |
| Week 24 | 14% | 32% | 17 (10, 24) |
| ACR 70 responsea | |||
| Week 16 | 1% | 14% | 13 (9, 17) |
| Week 24 | 4% | 19% | 15 (9, 20) |
| a Subjects with missing data at a visit were imputed as non-responders at that visit. Subjects who met escape criteria (less than 5% improvement in both tender and swollen joint counts) at Week 16 were allowed to initiate or increase the dose of the permitted concomitant medication and remained on the randomized group. Subjects who initiated or increased the dose of non-biologic DMARD or oral corticosteroids over baseline, discontinued study/study medication or initiated protocol prohibited medications/therapies for PsA prior to a visit were considered non-responders at that visit. | |||
The percentage of subjects achieving ACR20 response in PsA2 by visit is shown in Figure 1.
Figure 1: Subjects Achieving ACR 20 Response by Visit Through Week 24 in PsA2
 |
The results of the components of the ACR response criteria are shown in Table 6.
Table 6: Mean change (SDa) from Baseline in ACR Component Scores at Week 16 and 24 based on Observed Data
| PsA1 | PsA2 | |||
| Placebo (N=126) | TREMFYA100 mg q8w (N=127) | Placebo N=246 | TREMFYA100 mg q8w (N=248) | |
| No. of Swollen Joints | ||||
| Baseline | 10.1 (7.1) | 10.9 (9.3) | 12.3 (6.9) | 11.7 (6.8) |
| Mean change at Week 16 | -4.2 (7.0) | -7.3 (7.0) | -5.8 (7.1) | -7.2 (6.0) |
| Mean change at Week 24 | -5.1 (6.9) | -7.3 (8.0) | -6.4 (7.2) | -8.1 (6.1) |
| No. of Tender Joints | ||||
| Baseline | 19.8 (14.4) | 20.2 (14.5) | 21.6(13.1) | 19.8 (11.9) |
| Mean change at Week 16 | -4.5 (10.8) | -10.2 (10.4) | -6.8 (10.5) | -9.0 (9.4) |
| Mean change at Week 24 | -6.8 (13.0) | -10.5 (12.0) | -7.3 (11.2) | -10.4 (9.5) |
| Patient’s Assessment of Painb | ||||
| Baseline | 5.8 (2.2) | 6.0 (2.1) | 6.3 (1.8) | 6.3 (2.0) |
| Mean change at Week 16 | -0.8 (2.3) | -1.7 (2.4) | -0.9 (2.3) | -2.2 (2.5) |
| Mean change at Week 24 | -0.7 (2.4) | -2.2 (2.6) | -1.1 (2.4) | -2.5 (2.5) |
| Patient Global Assessmentb | ||||
| Baseline | 6.1 (2.2) | 6.5 (2.0) | 6.5 (1.8) | 6.5 (1.9) |
| Mean change at Week 16 | -1.0 (2.3) | -2.0 (2.6) | -1.0 (2.3) | -2.3 (2.6) |
| Mean change at Week 24 | -0.9 (2.5) | -2.5 (2.7) | -1.2 (2.6) | -2.5 (2.5) |
| Physician Global Assessmentb | ||||
| Baseline | 6.3 (1.7) | 6.2 (1.7) | 6.7 (1.5) | 6.6 (1.6) |
| Mean change at Week 16 | -1.9 (2.2) | -2.9 (2.4) | -2.1 (2.2) | -3.5 (2.3) |
| Mean change at Week 24 | -2.2 (2.3) | -3.5 (2.4) | -2.5 (2.3) | -3.8 (2.3) |
| Disability Index (HAQ-DI)c | ||||
| Baseline | 1.2 (0.7) | 1.2 (0.6) | 1.3 (0.6) | 1.3 (0.6) |
| Mean change at Week 16 | -0.1 (0.5) | -0.3 (0.5) | -0.1 (0.5) | -0.3 (0.5) |
| Mean change at Week 24 | -0.1 (0.5) | -0.3 (0.6) | -0.2 (0.5) | -0.4 (0.5) |
| CRP (mg/dL) | ||||
| Baseline | 1.4 (1.9) | 1.6 (2.4) | 2.1 (2.7) | 2.0 (2.4) |
| Mean change at Week 16 | -0.2 (1.5) | -0.6 (2.2) | -0.6 (2.5) | -1.0 (2.2) |
| Mean change at Week 24 | -0.0 (2.8) | -0.7 (2.1) | -0.5 (2.5) | -1.1 (2.2) |
| a SD= standard deviation b Assessment based on Visual Analog Scale (cm) with the left end indicating “no pain” (for patient’s assessment of pain), “very well” (for patient global assessment), or “no arthritis activity” (for physician global assessment) and the right end indicating “the worst possible pain” (for patient assessment of pain), “poor” (for patient global assessment), or “extremely active arthritis (for physician global assessment). c Disability Index of the Health Assessment Questionnaire; 0 = no difficulty to 3 = inability to perform, measures the patient’s ability to perform the following: dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living | ||||
Treatment with TREMFYA resulted in an improvement in the skin manifestations of psoriasis in subjects with PsA.
Treatment with TREMFYA resulted in improvement in dactylitis and enthesitis in patients with pre-existing dactylitis or enthesitis.
TREMFYA treated subjects in the TREMFYA 100 mg q8w group in both PsA1 and PsA2 showed greater mean improvement from baseline in physical function compared to subjects treated with placebo as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Weeks 16 and 24. In both studies, the proportion of HAQ-DI responders (≥0.35 improvement in HAQ-DI score) was greater in the TREMFYA q8w dose group compared to placebo at Weeks 16 and 24.
General health status was assessed by the Short Form health survey (SF-36). At Week 24, subjects in the TREMFYA 100 mg q8w dose group in both PsA1 and PsA2 showed greater improvement from baseline in the SF-36 physical component summary (PCS) compared with placebo. There was not a statistically significant improvement observed in the SF-36 MCS. At Week 24, there was numerical improvement in the physical functioning, role-physical, bodily-pain, general health, social-functioning and vitality domains but not in the role-emotional and mental health domains. Fatigue was assessed by the Functional Assessment of Chronic Illness Therapy-Fatigue score (FACIT-F) in Studies PsA1 and PsA2. Treatment with TREMFYA resulted in improvement in fatigue as measured by FACIT-F.
TREMFYA®
(trem fye´ ah)
(guselkumab) injection, for subcutaneous use
What is the most important information I should know about TREMFYA?
TREMFYA may cause serious side effects, including:
Tell your healthcare provider right away if you have an infection or have symptoms of an infection, including:
See “What are the possible side effects of TREMFYA?” for more information about side effects.
What is TREMFYA?
TREMFYA is a prescription medicine used to treat adults:
It is not known if TREMFYA is safe and effective in children under 18 years of age.
Do not use TREMFYA if you have had a serious allergic reaction to guselkumab or any of the other ingredients in TREMFYA. See the end of this Medication Guide for a complete list of ingredients in TREMFYA.
Before using TREMFYA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How should I use TREMFYA?
See the detailed “Instructions for Use” that comes with TREMFYA for information on how to prepare and inject a dose of TREMFYA, and how to properly throw away (dispose of) used TREMFYA prefilled syringes or One- Press injectors.
If you inject more TREMFYA than prescribed, call your healthcare provider right away.
What are the possible side effects of TREMFYA?
TREMFYA may cause serious side effects including:
The most common side effects of TREMFYA include:
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of TREMFYA
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TREMFYA for a condition for which it was not prescribed. Do not give TREMFYA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about TREMFYA that is written for health professionals.
What are the ingredients in TREMFYA?
Active ingredient: guselkumab
Inactive ingredients: L-histidine, L-histidine monohydrochloride monohydrate, polysorbate 80, sucrose and water for injection
Not made with natural rubber latex.
Instructions for Use
TREMFYA®
(trem fye´ ah)
(guselkumab) Prefilled Syringe
 |
Important
TREMFYA comes as a single-dose prefilled syringe containing one 100 mg dose.
Each TREMFYA prefilled syringe can only be used one time. Throw the used prefilled syringe away (See Step 3) after one dose, even if there is medicine left in it. Do not reuse your TREMFYA prefilled syringe.
If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA at home, you should receive training on the right way to prepare and inject TREMFYA using the prefilled syringe before attempting to inject. Do not try to inject yourself until you have been shown the right way to give the injections by your healthcare provider.
Read this Instructions for Use before using your TREMFYA prefilled syringe and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.
The TREMFYA prefilled syringe is intended for injection under the skin, not into the muscle or vein. After injection, the needle will retract into the body of the device and lock into place.
Storage information
Store in refrigerator at 36° to 46°F (2° to 8°C). Do not freeze TREMFYA prefilled syringe.
Keep TREMFYA prefilled syringe and all medicines out of reach of children. Do not shake your TREMFYA prefilled syringe.
Keep TREMFYA prefilled syringe in the original carton to protect from light and physical damage.
Prefilled syringe parts
Before Use
 |
After Use
 |
You will need these supplies:
Not provided in the TREMFYA prefilled syringe carton:
Prepare for your injection
 |
Inspect carton
Remove your TREMFYA prefilled syringe carton from the refrigerator.
Keep the prefilled syringe in the carton and let it sit on a flat surface at room temperature for at least 30 minutes before use.
Do not warm the prefilled syringe any other way.
Check the expiration date (‘EXP’) on the back panel of the carton.
Do not use your prefilled syringe if the expiration date has passed.
Do not inject TREMFYA if the perforations on the carton are broken.
Call your healthcare provider or pharmacist for a refill.
 |
Select from the following areas for your injection:
Do not inject into skin that is tender, bruised, red, hard, thick, scaly or affected by psoriasis.
 |
Wash your hands well with soap and warm water.
Wipe your chosen injection site with an alcohol swab and allow it to dry.
Do not touch, fan, or blow on the injection site after you have cleaned it.
 |
Take your TREMFYA prefilled syringe out of the carton.
Check the TREMFYA prefilled syringe liquid in the viewing window. It should be clear to slightly yellow and may contain tiny white or clear particles. You may also see one or more air bubbles.
This is normal.
Do not inject if the liquid is cloudy or discolored, or has large particles. Call your healthcare provider or pharmacist for a refill.
2. Inject TREMFYA using prefilled syringe
 |
Hold your prefilled syringe by the body and pull needle cover straight off.
It is normal to see a drop of liquid.
Inject TREMFYA within 5 minutes of removing the needle cover.
Do not put needle cover back on, as this may damage the needle or cause a needle stick injury.
Do not touch needle or let it touch any surface.
Do not use a TREMFYA prefilled syringe if it is dropped. Call your healthcare provider or pharmacist for a refill.
 |
Place your thumb, index and middle fingers directly under the finger flange, as shown.
Do not touch plunger or area above finger flange as this may cause the needle safety device to activate.
Use your other hand to pinch skin at the injection site. Position syringe at about a 45 degree angle to the skin.
It is important to pinch enough skin to inject under
2. Inject TREMFYA using prefilled syringe the skin and not into the muscle.
Insert needle with a quick, dart-like motion.
 |
Use your free hand to grasp the body of the prefilled syringe.
 |
Place thumb from the opposite hand on the plunger and press the plunger all the way down until it stops.
 |
The safety guard will cover the needle and lock into place, removing the needle from your skin.
3. After your injection
 |
Put your used TREMFYA prefilled syringe in an FDA-cleared sharps disposal container right away after use.
Do not throw away (dispose of) your TREMFYA prefilled syringe in your household trash.
Do not recycle your used sharps disposal container.
For more information, see “How should I dispose of the used prefilled syringe?”
 |
There may be a small amount of blood or liquid at the injection site. Hold pressure over your skin with a cotton ball or gauze pad until any bleeding stops.
Do not rub the injection site.
If needed, cover injection site with a bandage.
Need help?
Call your healthcare provider to talk about any questions you may have. For additional assistance or to share your feedback call 800-JANSSEN (800-526-7736).
How should I dispose of the used prefilled syringe?
If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.
For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: www.fda.gov/safesharpsdisposal
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Instructions for Use
TREMFYA®
(trem fye’ ah)
(guselkumab) One-Press Patient-Controlled Injector
Single Dose
 |
Important
TREMFYA comes in a single-dose One-Press injector containing one 100 mg dose. Each One-Press injector can only be used one time. Throw away (See Step 3) after one dose, even if there is medicine left in it. Do not reuse your One-Press injector.
If your healthcare provider decides that you or a caregiver may be able to give your injections of TREMFYA at home, you should receive training on the right way to prepare and inject TREMFYA using the One-Press injector. Do not try to inject yourself until you have been trained by your healthcare provider.
Please read this Instructions for Use before using your One-Press injector and each time you get a new One-Press injector. There may be new information. This leaflet does not take the place of talking with your healthcare provider about your medical condition or your treatment.
Storage information
Store in refrigerator at 36° to 46°F (2° to 8°C).
Do not freeze your One-Press injector.
Keep your One-Press injector and all medicines out of reach of children.
Do not shake your One-Press injector.
Keep your One-Press injector in the original carton to protect from light and physical damage.
Need help?
Call your healthcare provider to talk about any questions you may have. For additional assistance or to share your feedback call 800-JANSSEN (800-526-7736).
One-Press injector parts
 |
You will need:
Not provided in the carton:
 |
Inspect carton
Remove your One-Press injector carton from the refrigerator.
Keep your One-Press injector in the carton and let it sit on a flat surface at room temperature for at least 30 minutes before use.
Do not warm your One-Press injector any other way.
Check the expiration date (‘EXP’) on the carton.
Do not use your One-Press injector if the expiration date has passed.
Do not inject TREMFYA if the perforations on the carton are broken. Call your healthcare provider or pharmacist for a new One-Press injector.
 |
Choose injection site
Select from the following areas for your injection:
Do not inject into skin that is tender, bruised, red, hard, thick, scaly, or affected by psoriasis.
 |
Wash your hands well with soap and warm water.
Clean injection site
Wipe your chosen injection site with an alcohol swab and allow it to dry. Do not touch, fan, or blow on the injection site after you have cleaned it.
 |
Take your One-Press injector out of the carton.
Check the liquid in the window. It should be clear to slightly yellow and may contain tiny white or clear particles. You may also see one or more air bubbles. This is normal.
Do not inject if the liquid is cloudy or discolored, or has large particles. Call your healthcare provider or pharmacist for a new One-Press injector.
2. Inject TREMFYA using the One-Press injector
Twist and pull off bottom cap
 |
Keep hands away from the needle guard after the cap is removed.
Inject TREMFYA within 5 minutes of removing the cap.
Do not put the cap back on, this could damage the needle.
Do not use a One-Press injector if it is dropped after removing the cap. Call your  healthcare provider or pharmacist for a new One-Press injector.
 |
Position the One-Press injector straight onto the skin (about 90 degrees relative to injection site).
 |
Medication injects as you push. Do this at a speed that is comfortable for you.
Do not lift the One-Press injector during the injection. The needle guard will lock and the full dose will not be delivered.
 |
Injection is complete when the handle is pushed all the way down, you hear a click, and the teal body is no longer visible.
 |
The yellow band indicates that the needle guard is locked.
3. After your injection
Dispose of your One-Press injector
 |
Put your used One-Press injector in an FDA-cleared sharps disposal container right away after use.
Do not throw away (dispose of) your One-Press injector in your household trash.
Do not recycle your used sharps disposal container.
For more information, see “How should I dispose of the used One-Press injector?”.
 |
There may be a small amount of blood or liquid at the injection site. Hold pressure over your skin with a cotton ball or gauze pad until any bleeding stops.
Do not rub the injection site.
If needed, cover injection site with a bandage.
How should I dispose of the used One-Press injector?
If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes.
For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: www.fda.gov/safesharpsdisposal
This Instructions for Use has been approved by the U.S. Food and Drug
